GLP-1 receptor agonist therapy

Preclinical

GLP-1 receptor agonist therapy is one of 13 therapeutic programs targeting Obesity & Overweight. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Obesity & OverweightRecruiting

Obesity & OverweightPreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in Obesity & Overweight

#DrugCompanyPhaseTrials

Mazdutide

Eli Lilly

Phase 3

1 2

Ozempic

Novo Nordisk

Phase 2

2 3

AZD6234

AstraZeneca

Phase 2

1 4

AZD9550

AstraZeneca

Phase 2

1 5

Crestor

AstraZeneca

Preclinical

1 6

Semagludtide

Novo Nordisk

Phase 2

1 7

LUM-201

LLumos Pharma

Phase 2

1 8

Enobosarm

VVeru Inc.

Phase 2

1 9

CX11

CCorxel Pharmaceuticals

Phase 1

1 10

Incretin-Based Treatment

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Obesity & Overweight

NCT07740291

Q2 2027

Not yet recruiting

Morbid Obesity

NCT07668765

Clinical

Trials by Indication[1]

Obesity & Overweight1 trial

Tirzepatide Impact Assessment: Exploring Health and Wellness Outcomes

Recruiting·TTexas Tech University·Preclinical·NCT07740291·27 enrolled

Morbid Obesity1 trial

Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment

Not yet recruiting·GGazi University··NCT07668765·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GLP-1 receptor agonist therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for GLP-1 receptor agonist therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Gazi University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GGazi University

GLP-1 receptor agonist therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Obesity & Overweight1 trial

Morbid Obesity1 trial

References

Drug Info

Quick Facts

Related News